Connect Biopharma Holdings Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $64.0K | $26.0M | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $37.8M | $29.3M | $53.0M |
| SG&A Expense | $20.3M | $19.2M | $16.1M |
| Operating Income | $-58.1M | $-22.5M | $-69.1M |
| Operating Margin | -90,740.6% | -86.2% | — |
| Interest Expense | — | — | $23.0K |
| Pretax Income | $-55.3M | $-15.4M | $-62.0M |
| Income Tax Expense | $197.0K | $223.0K | $120.0K |
| Net Income | $-55.5M | $-15.6M | $-62.1M |
| Net Margin | -86,687.5% | -60.0% | — |
| EPS (Basic) | $-1.00 | $-0.28 | $-1.13 |
| EPS (Diluted) | $-1.00 | $-0.28 | $-1.13 |
| Shares Outstanding (Basic) | 55.7M | 55.2M | 55.1M |
| Shares Outstanding (Diluted) | 55.7M | 55.2M | 55.1M |
| Dividends Per Share | — | — | — |